Nipah Virus: Heightened Scrutiny Following West Bengal Detections

Recent cases of the Nipah virus detected in West Bengal, India, have prompted several Asian countries to implement heightened health screening measures for travelers. The Nipah virus, a zoonotic pathogen with a high fatality rate, currently has no approved vaccine or specific treatment, leading to intensified global surveillance and ongoing research into its mechanisms and potential therapies.

Current Situation and International Response

Two cases of Nipah virus were recently confirmed in West Bengal, India. Authorities identified and traced 196 close contacts of the infected individuals; all tested negative and were asymptomatic. These cases, which included healthcare workers, mark the first in West Bengal in nearly two decades. The U.S. Centers for Disease Control and Prevention (CDC) is monitoring the situation.

In response, several countries across Asia have increased health screenings:

• Thailand initiated airport screenings at Bangkok and Phuket for passengers arriving from West Bengal, requiring health declarations.
• Malaysia increased health screening at international ports of entry, specifically for arrivals from at-risk countries.
• Singapore implemented new screening and testing protocols and temperature checks at airports for passengers from India.
• Nepal established screenings at Kathmandu airport and land border points with India, declaring a "high alert."
• Hong Kong initiated temperature checks at airports for arrivals from India.
• Indonesia, Vietnam, and Pakistan have also reportedly increased health screening measures.
• Taiwan has proposed classifying Nipah virus as a "Category 5 disease," which denotes an emerging or rare infection with significant public health risks.

Australia's Federal Health Minister stated that no immediate plans exist to tighten border controls, citing sufficient existing protocols and hopes for containment of the current outbreak.

About Nipah Virus

Nipah virus is a highly lethal zoonotic pathogen, meaning it transmits from animals to humans. It is part of the henipavirus group, which also includes the Hendra virus, and originates primarily from fruit bats. The World Health Organization (WHO) identifies Nipah as a priority pathogen, while the CDC classifies it as a biosafety level four pathogen, the highest category.

Transmission

The virus can spread through multiple pathways:

• Animal-to-human: Direct contact with infected animals (e.g., bats, pigs) or their bodily fluids.
• Contaminated food: Consumption of fruit or fruit products, such as raw date palm juice, contaminated by infected bat fluids.
• Human-to-human: Close contact with an infected individual or their bodily fluids. This method of transmission is considered less common and less efficient than airborne diseases.

Symptoms and Severity

The incubation period typically ranges from 4 to 21 days. Symptoms can vary and may initially resemble the flu, including fever, headaches, muscle pain, vomiting, and sore throat. These can progress to severe conditions such as:

• Pneumonia and other respiratory symptoms.
• Encephalitis (brain inflammation), a primary concern contributing to its high fatality rate.
• Drowsiness, disorientation, seizures, altered consciousness, and potentially a coma.
• In some cases, individuals may be asymptomatic.

The fatality rate for Nipah virus ranges from 40% to 75%. Survivors may experience permanent neurological damage, including persistent convulsions, personality changes, long-term fatigue, or relapsed encephalitis years later.

Historical Context

Nipah virus was first identified in 1998 during an outbreak among pig farmers in Malaysia, which subsequently spread to Singapore, resulting in over 100 fatalities and the culling of one million pigs. Since then, the virus has caused repeated outbreaks in South and Southeast Asia. Bangladesh has experienced annual outbreaks, with over 100 deaths since 2001. India has also seen multiple outbreaks, including in West Bengal in 2001 and 2007, and in Kerala in 2018 and 2023. Globally, fewer than 1,000 human infections have been recorded since its discovery.

Treatment and Research

Currently, there is no widely available specific treatment or vaccine for Nipah virus. Medical care focuses on intensive supportive measures to manage symptoms, such as fever, headache, and brain swelling.

However, research and development are ongoing:

• A treatment called m102.4 is under development in Australia; a Phase 1 trial in 2020 indicated it was well tolerated by healthy participants.
• Other candidate vaccines and antiviral drugs are in development.
• A monoclonal antibody has completed Phase 1 clinical trials and is being used on a compassionate basis.
• The antiviral drug remdesivir, used for COVID-19, is being investigated for potential efficacy against Nipah virus.
• Australian scientists from Monash University, the University of Melbourne, and CSIRO are researching how henipaviruses control infected cells. Recent studies published in Nature Communications identified a mechanism where viral proteins interact with a human protein called Treacle, involved in the cell's DNA damage response. This interaction appears to modify cellular mechanisms to aid viral proliferation, suggesting a new avenue for antiviral drug development.

Prevention and Outlook

The WHO advises several measures to reduce infection risk in affected areas:

• Avoiding bats and infected animals.
• Washing and peeling fruit.
• Discarding fruit with bat bite marks.
• Maintaining proper hygiene when in contact with infected individuals.

Experts generally assess that a global emergency from current Nipah cases is unlikely due to its less efficient person-to-person transmission compared to airborne diseases like COVID-19.

Outbreaks are typically small and localized, and the virus's relatively long incubation period can assist in containment efforts through isolation and contact tracing. However, the virus remains a significant public health concern due to its high case fatality rate and epidemic potential, particularly in regions where fruit bats are endemic. Researchers also suggest that factors such as habitat destruction and climate change could potentially increase interactions between infected animals and humans, leading to a rise in such rare illnesses.